🟢 Hims Hers Health is trading 4.11% up today after JPMorgan resumed coverage at Neutral

Hims Hers Health is trading 4.11% up at $28.64 after JPMorgan resumed coverage on September 11, 2026, with a Neutral rating and a $32 price target.

• The action followed JPMorgan’s prior coverage suspension.
• The analyst cited ongoing GLP-1 transition risks, including challenges moving from compounded to branded weight-loss treatments.
• The broader market is lower, suggesting company-specific sentiment is supporting the gain.